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Abstract
Objective We discuss the evidence on the occurrence of de novo seizures in patients with COVID-19, the consequences of this
catastrophic disease in people with epilepsy (PWE), and the electroencephalographic (EEG) findings in patients with COVID-19.
Methods This systematic review was prepared according to the recommendations of the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses statement. MEDLINE, Scopus, and Embase from inception to August 15, 2020 were
systematically searched. These key words were used: “COVID” AND “seizure” OR “epilepsy” OR “EEG” OR “status epilep-
ticus” OR “electroencephalography”.
Results We could identify 62 related manuscripts. Many studies were case reports or case series of patients with COVID-19 and
seizures. PWE showed more psychological distress than healthy controls. Many cases with new-onset focal seizures, serial
seizures, and status epilepticus have been reported in the literature. EEG studies have been significantly ignored and underused
globally.
Conclusion Many PWE perceived significant disruption in the quality of care to them, and some people reported increase in their
seizure frequency since the onset of the pandemic. Telemedicine is a helpful technology that may improve access to the needed
care for PWE in these difficult times. De novo seizures may occur in people with COVID-19 and they may happen in a variety of
forms. In addition to prolonged EEG monitoring, performing a through metabolic investigation, electrocardiogram, brain imag-
ing, and a careful review of all medications are necessary steps. The susceptibility of PWE to contracting COVID-19 should be
investigated further.
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Introduction
Since late 2019, the world has been experiencing a catastroph-
ic pandemic of a new coronavirus disease (COVID-19) caused
by SARS-CoV2.[1]. Previous outbreaks of coronaviruses con-
sist of the severe acute respiratory syndrome (SARS) in 2002
and the Middle East respiratory syndrome (MERS) in
2012.[2] Coronaviruses primarily target the human respiratory
system. However, they have also been associated with neuro-
logical manifestations (e.g., seizures, change in mental status,
and encephalitis).[2, 3]. Neurotropic and neuroinvasive capa-
bilities of coronaviruses have been described before.[4].
The signs and symptoms of COVID-19 infection often ap-
pear after an incubation period of about five days [1]. The
most frequent manifestations at the onset of COVID-19 illness
are fever, cough, loss of smell and taste, and fatigue; other
manifestations may include headache, hemoptysis, diarrhea,
and dyspnea. In patients with severe disease, pneumonia,
acute respiratory distress syndrome, organ failure, metabolic
derangements, and acute cardiac injury may happen [1]. It is
reasonable to expect that some patients with COVID-19 de-
velop seizures as a consequence of hypoxemia, organ failure,
metabolic derangements, drug-drug interactions, or even brain
damage that may occur in patients with COVID-19 [2, 3, 5].
On the other hand, information on the susceptibility of people
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with epilepsy (PWE) to contracting COVID-19 and the con-
sequences and challenges of this catastrophic disease in PWE
are scarce.
In the current systematic review, wewill discuss the evidence
on the occurrence of de novo seizures in patients with COVID-
19 (the types of seizures and the etiology), the consequences,
and challenges of this catastrophic disease in PWE (e.g., access
to care and seizure control), and finally, the electroencephalo-
graphic (EEG) findings in patients with COVID-19. We will
also provide suggestions to tackle the abovementioned issues
based on the best available evidence.
Methods
This manuscript was prepared according to the recommenda-
tions of the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [6, 7] (Fig. 1 and
Table 1). MEDLINE (accessed from PubMed), Scopus, and
Embase from inception to August 15, 2020 were systemati-
cally searched for related published articles. In all electronic
databases, the following search strategy was implemented and
these key words (in the title/abstract) were used: “COVID”
AND “seizure” OR “epilepsy” OR “EEG” OR “status epilep-
ticus” OR “electroencephalography”. Articles written in
English were all included. To ensure literature saturation, the
authors scanned the reference lists of the included studies or
relevant articles identified through the search. All authors par-
ticipated through each phase of the review independently
(screening, eligibility, and inclusion). They obtained full re-
ports for all titles that appeared to meet the inclusion criteria or
where there was any uncertainty. They resolved any disagree-
ment through discussions. Neither of the authors were blind to
the journal titles nor the study authors or institutions.
The following data were extracted from the included stud-
ies: study authors, study location, study designs, main results,
and limitations. The methodological quality of the included
studies was assessed by the authors. The class of evidence was
defined following the American Academy of Neurology
criteria for classification of evidence in studies of causation
(Appendix, Table 5) [8].
Standard protocol approvals, registrations,
and patient consents
The Shiraz University of Medical Sciences Institutional
Review Board approved this study and systematic review.
Results
Through the search strategy, we could identify 62 related
manuscripts (Tables 2, 3, and 4) [9–70]. Only one paper
provided class 2 evidence and 11 papers provided class 3
evidence; the rest of the publications provided class 4 evi-
dence. Many studies were case reports or case series
of patients with COVID-19 and seizures. The rest of
the publications were surveys or observational studies
(Tables 2, 3, and 4). Below, we summarize the results
of this systematic review:
1.1. Epilepsy related papers (Table 2): One cross-sectional
study of 21 patients with active epilepsy and COVID-19
out of 1537 patients (1.4%) with level 2 of evidence
showed that the cumulative incidence of COVID-19 in
people with epilepsy was higher compared with the
population without epilepsy (1.2% vs. 0.5%) [9].
Furthermore, the total case fatality rate was higher in
PWE compared to patients without active epilepsy
(23.8% vs. 3.6%; p < 0.001) [9]. However, these results
were obtained based on a small number of PWE (21
persons) and should be interpreted with caution.
In addition, in another study, among 5700 PWE,
who were managed at the studied centers, only 14
people tested positive for SARS-CoV-2, without
obvious impacts on their epilepsy [18]. Six sur-
veys of PWE showed that many people perceived
significant disruption in the quality and availability
of care to them (31 to 95%), as well as increased
stress and social isolation, and increase in seizure
frequency (6 to 35%) since the onset of the pan-
demic [11, 12, 14–17]. One observational compar-
ative study confirmed that PWE showed more psy-
chological distress than healthy controls, and they
spent significantly more time following the
COVID-19 outbreak news [13]. Finally, four stud-
ies showed that telemedicine may improve access
to specialized care for PWE in these difficult
times [10, 20–22]. The development of an epilep-
sy electronic patient portal may promote improved
patient-clinician partnerships and facilitate patient
self-management [23]
1.2. Seizure-related papers (Table 3): While one retrospec-
tive study reported no seizures in 304 patients with
COVID-19 [25], multiple studies refuted that finding
[24, 26–29]. Furthermore, many cases with new-onset
focal seizures, serial seizures, and status epilepticus
have been reported in the literature [30–49, 51, 63].
The etiology of seizure(s) in the reported patients was
most likely multifactorial, as many of them had comor-
bidities (e.g., diabetes and kidney disease),
multiorgan failure, metabolic derangements, hyp-
oxemia, etc. In addition, all these patients received
many medications [33–47]. However, some of the
patients had specific neurological problems (e.g.,
encephalitis [33, 40, 70] and cerebrovascular
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events [38, 42, 43, 51, 59]). SARS-CoV-2 RNA
was detected in the cerebrospinal fluid (CSF) in
two patients [40, 53]; however, many other studies
that tested for this had negative results [36, 42,
44, 46, 52, 59, 60, 64, 67, 70]. It should be em-
phasized that many centers did not investigate the
patients with COVID-19, who had seizures, thor-
oughly. For example, many patients did not have
EEG exams, and in a significant number of them
CSF analysis and even brain imaging studies were
not performed.
1.3. EEG-related papers (Table 4): While change in mental
status has frequently been reported in patients with
COVID-19 [26, 27, 55, 60, 65, 66, 70], and while there
are many reports on clinical and subclinical seizures and
status epilepticus in these patients [33–47, 63, 66], EEG
studies have been significantly ignored and underused
in these patients globally. Three studies showed that
EEG services have been significantly disrupted by the
pandemic of COVID-19 [18, 19, 57]. Three other
studies showed that many of the patients with
COVID-19 and encephalopathy/seizures had epi-
leptiform discharges/seizures in their EEG [29,
54, 55]. One study of two patients with COVID-
19 and encephalopathy suggested a unique EEG
pattern with continuous, slightly asymmetric,
monomorphic, diphasic, delta slow waves with
greater amplitude over both frontal areas and with
a periodic organization [58]. Finally, two studies
suggested that quantitative EEG (QEEG) features
may be useful for diagnosis and prognostication of
the neurological outcome in critically ill patients
with COVID-19 [61, 62]. While studies investigat-
ing EEG in patients with COVID-19 did not find
a consistent and specific neurophysiological pat-
tern in critically ill patients, the authors should
describe the EEG findings more appropriately, ad-
hering to the standardized terminologies, in future
studies [71].
Discussion
The evidence on the susceptibility of PWE to contracting
COVID-19 and the consequences of this catastrophic disease
in PWE is scarce. A recent systematic review suggested that
patients with pre-existing neurological disorders (including
epilepsy) and COVID-19 may develop exacerbation of their
neurological problems and also severe COVID-19 [72]. This
significant concern should be addressed in the future through
well-designed prospective cohort studies with all relevant con-
founders controlled. However, evidence showed that many
PWE perceived significant disruption in the quality and
availability of care to them, and some people reported increase
in their seizure frequency since the onset of the pandemic [11,
12, 14, 16, 17]. Previous global experiences confirm this piece
of evidence. A study of 227 PWE during the SARS outbreak
in 2003 in Taiwan demonstrated that 22% of them did not
receive their medications due to loss of contact with their
healthcare providers; 12% of them experienced seizure control
status worsening [73]. In addition, many PWE may have in-
creased stress and social isolation, even more than that in
others, during such circumstances as COVID-19 pan-
demic [12–15]. During pandemics and other difficult
and catastrophic circumstances (e.g., wars and mass dis-
placements), healthcare workers should focus not only
on seizure control status of their patients, but also on
the mental health of PWE [13]. In such times, stress is
associated with increased seizures in PWE [11], and
stress management strategies may play a significant role
in helping these patients cope with their ongoing prob-
lems more successfully. Research shows that people
who follow COVID-19 news the most, experience more
anxiety and stress [74, 75]. Healthcare providers should
advise their patients to avoid following COVID-19 news
frequently. In addition, it might be helpful to use digital
communication methods such as social networks to pre-
vent social isolation [75]. Similarly, many patients with
epilepsy may have depressive symptoms, particularly
during such difficult times, and several factors related
to epilepsy (e.g., seizure frequency and quality of life)
are significantly correlated with depressive symptoms
[76]. Therefore, it is helpful to screen all PWE for anx-
iety, stress, and depression, and treat any psychological
problems that patients may have, particularly during a
pandemic or other difficult circumstances.
Telemedicine is a viable and helpful technology that
may improve access to the needed care for PWE in
these difficult times [10, 20, 22]. During a pandemic
such as what we are experiencing now, telemedicine,
particularly video consultations, ought to be promoted
in order to reduce the risk of disease transmission
[77]. Telemedicine has been shown to improve access
to care for PWE in difficult circumstances (e.g., people
living in rural areas) [78]. However, many countries do
not have the infrastructure or the regulatory frameworks
to authorize, integrate, and reimburse telemedicine ser-
vices [77].
Another important issue is the occurrence of new-onset
seizures in people with COVID-19. While seizure is not a
common manifestation of COVID-19, it may happen in a
variety of forms (e.g., focal motor, tonic-clonic, convulsive
status epilepticus, and nonconvulsive status epilepticus) [28,
30–47]. On the other hand, many patients with severe
COVID-19 may have changes in their mental status [26, 27].
When visiting a patient who is in a critical medical condition
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and has a change in mental status, the treating healthcare pro-
fessional should make sure that nonconvulsive status epilep-
ticus is not a part of the clinical scenario. Prolonged EEG
monitoring is required in these circumstances [3].
Electroencephalography is probably one of the most useful
tests to help identify the etiology of seizures and/or change
in mental status in critically ill patients, including those with
COVID-19; and at the same time, it is probably the most
neglected test so far in the management process of these pa-
tients globally. It is helpful to describe the EEG findings in a
systematic and consistent manner in order to characterize any
possible distinguishing and/or prognosticating EEG patterns
in patients with COVID-19. Finally, quantitative EEG may
also be useful for diagnosis and prognostication of the
neurological outcome in critically ill patients with
COVID-19 [61, 62].
Seizures may happen as a consequence of hypoxia, meta-
bolic derangements, organ failure, medications, or brain dam-
age that could happen in people with COVID-19 [3, 5]. If a
patient with COVID-19 develops a seizure, one should try to
Table 1 The search keywords included “COVID” and “Epilepsy/Seizure” in the title/abstract
Medline (PubMed) Scopus Embase
Keywords (& COVID) Primary hints Relevant articles Primary hints Relevant articles Primary hints Relevant articles
Epilepsy 55 23 85 25 (24 duplicates)* 154 28 (28 duplicates)
Seizure 42 23 (11 duplicates) 112 28 (21 duplicates) 122 22 (22 duplicates)
EEG 29 16 (6 duplicates) 26 5 (5 duplicates) 50 13 (13 duplicates)
Electroencephalography 15 12 (7 duplicates) 43 11 (11 duplicates) 42 11 (11 duplicates)
Status epilepticus 19 13 (9 duplicates) 15 15 (15 duplicates) 32 8 (8 duplicates)
*Duplicates: already found in previous searches
Records idenfied through database searching
















Addional records idenfied 
through other sources
(n = 0)
Records screened (tle and abstract)
(n = 841)
Records screened for duplicity 
(n = 253)
Records excluded 
(n =  191)
Full-text arcles assessed 
for eligibility
(n = 62)
Full-text arcles excluded, with 
reasons
(n =  0)
Studies included in 
qualitave synthesis
(n = 62)
Records excluded (not related)
(n =  588)
Records from other sources 
(n =  0)
Fig. 1 Preferred Reporting Items
for Systematic Reviews and
Meta-Analyses (PRISMA) flow
diagram of the study
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determine the etiology of the seizure and manage the cause
(e.g., hypoxia and metabolic derangements) immediately. In
addition to prolonged EEG monitoring, performing a thor-
ough metabolic investigation, electrocardiogram, brain
imaging, and a careful review of all medications (for
adverse drug reactions and also drug-drug interactions)
are necessary steps. CSF analysis is also necessary, at
least to investigate other causes for acute symptomatic
seizures that may happen concomitantly or that may
mimic the clinical picture of COVID-19 (e.g., herpes
simplex virus-1 encephalitis) [79]. In addition, it is of-
ten necessary to start an antiseizure medication (ASM)
for a patient with COVID-19 and seizure(s); this is to
abort prolonged seizures and also to prevent further sei-
zures from happening [3]. It should be emphasized that
patients with acute symptomatic seizures do not need
long-term ASM therapy after the period of acute illness,
unless a subsequent seizure happens [80]. For a com-
prehensive review on these issues, please refer to the
references [3, 5, 81].
Conclusion
What we know and should pay more attention to
Many PWE perceived significant disruption in the quality and
availability of care to them, and some people reported increase
in their seizure frequency since the onset of the pandemic. In
addition, many PWE may have increased stress and anxiety.
During pandemics and other difficult and catastrophic circum-
stances, healthcare workers should focus not only on seizure
control status of their patients, but also on the mental health of
PWE.
Telemedicine is a viable and helpful technology that
may improve access to the needed care for PWE in
these difficult times. The current COVID-19 pandemic
is a strong call to develop the required infrastructure
and to adopt the appropriate regulatory frameworks
for implementation of telemedicine services globally
[77].
De novo seizures may occur in people with COVID-19,
and they may happen in a variety of forms (e.g., focal motor,
tonic-clonic, convulsive status epilepticus, nonconvulsive sta-
tus epilepticus, and post SARS-CoV2 autoimmune encepha-
litis associated with new-onset refractory status epilepticus
(NORSE) [82, 83]). Furthermore, many patients with severe
COVID-19may have change inmental status. If a patient with
COVID-19 develops a seizure or change in mental sta-
tus, one should try to determine the etiology and man-
age the cause immediately. In addition to prolonged
EEG monitoring, performing a thorough metabolic in-
vestigation, electrocardiogram, brain imaging, CSF anal-
ysis, and a careful review of all medications are neces-
sary steps.
What we do not know yet and should be investigated
further
The evidence on the susceptibility of PWE to contracting
COVID-19 and the consequences of this catastrophic disease
in PWE is scarce. This significant concern should be ad-
dressed in the future through well-designed prospective cohort
studies with all relevant confounders controlled.
SARS-CoV-2 RNA was detected in the CSF in two pa-
tients, but many other studies that tested for this had negative
results. This is important to clarify the role of neurtropism and
neuroinvasiveness of this virus in causing seizures in future
studies.
It is not clear whether there is a unique EEG pattern for
COVID-19 encephalopathy. It is helpful to describe the EEG
findings in a systematic and consistent manner in order to
characterize any possible distinguishing and/or prognosticat-
ing EEG patterns in patients with COVID-19.
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